Alderley Park Companies Receive Bionow Awards

Drs Michael Morton and Richard Knight thoroughly enjoyed the Bionow 2018 Awards Dinner at the Mere Golf Resort & Spa, Cheshire on 29th November.

The awards which recognise excellence, outstanding achievement and enterprise in a sector that is worth more than £13bn to the North’s economy, were sponsored by Manchester Science Partnerships, Alderley Park, Appleyard Lees, DLA Piper and World Courier.

ApconiX, who won last year’s Start-Up of The Year Award, were thrilled to see Alderley Park companies among the winners again this year.

Blueberry Therapeutics won the Company of The Year Award. Blueberry has exclusive worldwide access to a nanodelivery platform, which significantly enhances delivery of drugs into cells and tissues. This is used to create safe, effective “nanomedicines” to treat several serious unmet medical needs.  Blueberry has had a remarkable year, including its BB2603 Phase I/II trial successfully meeting its primary endpoint in patients with both onychomycosis (fungal nail infection) and concomitant tinea pedis (athletes foot), as well as completing its £10m series B Fundraising.

Seda Pharmaceutical Development Services won the Technical Service Award.  Seda enable the rapid and efficient development of optimal medicinal products.  The company provides coherent and synergistic support across the four key disciplines of Chemistry Manufacturing and Controls (CMC), Drug Delivery System Scouting, Clinical Pharmacology and Biopharmaceutics and Biotech Investment Support.

“Having worked with both companies and watched them grow from strength to strength over recent years, we couldn’t be more delighted to see their hard work and success recognised,” commented Mike.

By |2018-12-16T19:10:57+00:00December 16th, 2018|Events|Comments Off on Alderley Park Companies Receive Bionow Awards

About the Author:

Dr Michael Morton, PhD, Director and Cofounder, ApconiX, UK, an integrated toxicology and ion channel company that brings together a team of world-renowned nonclinical safety experts with over 400 years of drug discovery and development experience. Mike graduated from the University of Wolverhampton with a degree in Biomedical Sciences and then aspiration to work in hospital pathology. Having finished his Sandwich placement in Clinical Biochemistry at Sandwell Hospital and Mike subsequently gained a MSc in Clinical Biochemistry from the University of Manchester and carried out research into porphyrin metabolism. Moving to the University of Leeds, Mike completed his PhD in Pharmacology at researching adenosine receptor expression in the rat kidney . Mike was introduced to ion channels as a Post-Doc at Leeds and Yale University, patching with the likes of Fred Sigworth and Steve Hebert, then joined the Global Ion Channel Initiative at AstraZeneca. Mike worked at AstraZeneca for eight years before founding ApconiX with Professor Ruth Roberts and Dr Richard Knight. Mike has a serious passion for ion channels. And he’s very good at them . He is a serious scientist (with a serious sense of humour) who wants to make sure that every customer understands the consequences of the results he obtains and works with his colleagues to ensure a better decision is made on drug safety.